Vitamin D Deficiency Clinical Trial
Official title:
Knowledge Innovation Project of CAS - Genetic and Nutritional Association Studies on Metabolism-related Diseases in Chinese Population -- Vitamin D Intervention Study
This is a double-blind, randomized, placebo-controlled trial. Based on inclusion and
exclusion criteria, 400 eligible volunteers, who were 20-45 years, with 25-hydroxyvitamin D
between 12.5-50 nmol/L and BMI between 18.5-28 kg/m2, were enrolled and randomly assigned to
placebo or 2000 IU/d vitamin D3 arm, after taking placebo for one week. The study protocol
was approved by the Ethics Committee of Huadong Hospital Affiliated to Fudan University,
Shanghai and all participants provided written informed consents.In this 2-arm RCT we aimed
to systematically investigate the effect of:
1. vitamin D3 supplement on serum 25(OH)D levels and the modifying factors;
2. genetic and non-genetic variants on vitamin D bioavailability;
3. vitamin D3 supplementation on metabolic profiles and circulating bone-turnover markers
At present time, the Recommended Dietary Allowance (RDA) and the tolerable upper intake
level (UL) for vitamin D are 200 IU/day and 800 IU/day for Chinese aged 11-50 years,
respectively. On the other hand, the RDA and UL for vitamin D for the same age group in USA
are 600IU/day and 4000IU/day, respectively. Indeed, recent epidemiological studies suggested
that serum 25-hydroxyvitamin D [25(OH)D] concentration ≥75 nmol/L appeared to be optimal for
preventing cardiometabolic diseases and improving bone health. To achieve this goal, a daily
intake of 1000 IU or equivalent amount from other sources, is needed, which is twice as much
as the RDA recommended by Chinese Nutrition Society. Except for those individuals with
hypersensitive conditions, daily intake less than 10,000 IU of vitamin D have not shown
overt adverse effects based upon the studies conducted in Western populations.
Since vitamin D metabolic rate and its relationship with health outcomes may vary across
different ethnical groups and most available data so far were from Caucasians populations,
it remains to be elucidated whether the findings from Western population could apply
directly to Asian peoples like Chinese. Recently, our group has conducted the first
relatively large-scale study in Asian to evaluate the association between 25(OH)D and risk
of metabolic syndrome. It was found that the geometric mean of plasma 25(OH)D in these
Chinese adults aged 50-70 years from Beijing and Shanghai (n=3210) was 40.36 nmol/l and
percentage of vitamin D deficiency [25(OH)D <50 nmol/l] and insufficiency (50 ≤ 25(OH)D < 75
nmol/l) were 69.2% and 24.4%, respectively. Comparing the lowest with the highest 25(OH)D
quintile (≤28.7 nmol/l vs. ≥57.7 nmol/l), the odds ratio for metabolic syndrome (MetS) was
1.52 (95% CI 1.17-1.98, P for trend = 0.0002), after multiple adjustment. Significant
inverse associations also existed between 25(OH)D and most of MetS components, plus HbA1c.
Moreover, low plasma 25(OH)D level was found to be associated with increased insulin
resistance index (homeostasis model assessment of insulin resistance, HOMA-IR) in those
overweight and obese individuals (BMI ≥24 kg/m2),. (Lu et al., Diabetes Care, 2009).
According to the data from 2002 China National Nutrition Survey, high prevalence of vitamin
D deficiency also exited in Chinese children aged 1-3 years and approximate 82% of them had
circulating 25(OH)D ≤ 50nmol/L. In consistent with our finding, a report from a
population-based Korea study showed that the association between 25(OH)D and insulin
resistance was modified by BMI status (Choi et al.,The Journal of Nutrition,2011).
In our recent genetic study, it was found that genetic variants at GC and NADSYN1/DHCR7 were
significantly associated with circulating 25(OH)D levels while marginal association between
CYP2R1-rs2060793 and 25(OH)D levels was observed only in the Shanghai subpopulation (Lu et
al., Human Genetics 2011). In addition, we developed a genetic risk score (GRS) to evaluate
the combined effect of three SNPs (rs4588, rs1790349 and rs2060793) from GC, NADSYN1/DHCR7
and CYP2R. Notably, the average plasma 25(OH)D concentration in individuals with 5-6 risk
allele was 11.4 nmol/l lower than those without risk allele. Indeed, previous studies
suggested that intake of 100 IU vitamin D could only raise circulating 25(OH)D by 2.5
nmol/l, implicating that 450 IU of extra vitamin D is required for these high risk
individuals. The possible interpretations for such a high prevalence of poor vitamin D
nutrition among Chinese may be due to the factors: (1) unlike United States and other
Western countries, few, if any, vitamin D enriched or fortified foods are available in China;
(2) Chinese, particularly women, like to have pale skin color, who therefore frequently
utilize sunscreen and umbrella to prevent sun exposure. (3) approximate 318 million people
are living in Heilongjiang, Shaanxi, Jilin, Shanxi, Liaoning, Qinghai, Gansu, Inner
Mongolia, Xinjiang, and Hebei provinces, the areas with latitude N37°, which was previously
showed to prevent skin synthesizing sufficient vitamin D during winter time. Collectively,
all of these factors suggest that large proportions of Chinese may suffer vitamin D
insufficiency or deficiency whereas the current RDA in China might be too low to provide
adequate vitamin D for people's health. In order to fill up this gap, therefore, it is
essential to study the bioavailability following vitamin D intervention and also identify
the effects of genetic variants and other factors on vitamin D metabolism and associated
health outcomes. Ultimately, the current study will provide important evidence for
establishing optimal vitamin D requirement for Chinese people.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05459298 -
ViDES Trial (Vitamin D Extra Supplementation)
|
N/A | |
| Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
| Completed |
NCT04476511 -
The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules
|
Phase 3 | |
| Completed |
NCT03920150 -
Vitamin D 24'000 IU for Oral Intermittent Supplementation
|
Phase 3 | |
| Completed |
NCT03264625 -
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
|
Phase 2 | |
| Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
| Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
| Completed |
NCT05506696 -
Vitamin D Supplementation Study
|
N/A | |
| Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
| Completed |
NCT03234218 -
Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
|
||
| Completed |
NCT02906319 -
Vitamin D and HbA1c Levels in Diabetic Patients With CKD
|
N/A | |
| Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
| Completed |
NCT02714361 -
A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women
|
N/A | |
| Completed |
NCT02118129 -
Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.
|
N/A | |
| Completed |
NCT02275650 -
The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter
|
N/A | |
| Not yet recruiting |
NCT01419821 -
Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5
|
N/A | |
| Completed |
NCT02187146 -
The Effects of Serum Vitamin D and IVF Outcome
|
N/A | |
| Completed |
NCT01651000 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 | |
| Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 |